» Articles » PMID: 32021454

MicroRNA-802 Inhibits Cell Proliferation and Induces Apoptosis in Human Laryngeal Cancer by Targeting CAMP-Regulated Phosphoprotein 19

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2020 Feb 6
PMID 32021454
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: miR-802 plays a key role in cancer progression and development. The purpose of this work is to investigate the functional role of miR-802 in laryngeal cancer and to elucidate the function of miR-802 and cAMP-regulated phosphoprotein 19 (ARPP19) on laryngeal cancer.

Methods: RT-qPCR was applied to study the expression level of ARPP19 and miR-802 in the laryngeal carcinoma cell lines and tissues. CCK-8, colony formation, flow cytometry (FACS) assay were used to study the effect of ARPP19 and miR-802 on apoptosis, proliferation, and cell cycle of laryngeal carcinoma cells. Target gene prediction and luciferase reporter gene assay were applied to identify target gene of miR-802. The transcriptional mRNA and protein expression levels of ARPP19 were measured by RT-qPCR or Western blotting.

Results: miR-802 was down-regulated in laryngeal carcinoma cell lines and tissues. Laryngeal cancer cells transfected by miR-802 mimic were significantly inhibited in the terms of cell colony formation and proliferation. Furthermore, miR-802 can inhibit the expression level of ARPP19 by directly targeting the 3' untranslated region (3'-UTR) of ARPP19. Overexpression of the ARPP19 gene can reverse the suppressive effect of miR-802 on laryngeal cancer cells.

Conclusion: miR-802 can exert tumor suppressor effects in laryngeal carcinoma by targeting ARPP19, indicating that miR-802 protein may play a role of potential therapeutic target for clinical laryngeal cancer.

Citing Articles

PP2A-B55: substrates and regulators in the control of cellular functions.

Amin P, Awal S, Vigneron S, Roque S, Mechali F, Labbe J Oncogene. 2021; 41(1):1-14.

PMID: 34686773 DOI: 10.1038/s41388-021-02068-x.


Dysfunction of miR-802 in tumors.

Gao T, Zou M, Shen T, Duan S J Clin Lab Anal. 2021; 35(11):e23989.

PMID: 34558723 PMC: 8605121. DOI: 10.1002/jcla.23989.


Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma.

Yu S, Cai L, Liu C, Gu R, Cai L, Zhuo L Mol Med. 2021; 27(1):36.

PMID: 33832428 PMC: 8034091. DOI: 10.1186/s10020-021-00294-3.


PP2A-B55 Holoenzyme Regulation and Cancer.

Goguet-Rubio P, Amin P, Awal S, Vigneron S, Charrasse S, Mechali F Biomolecules. 2020; 10(11).

PMID: 33266510 PMC: 7700614. DOI: 10.3390/biom10111586.


MicroRNA-802 Suppresses Tumorigenesis of Colorectal Cancer via Regulating UBN2.

Yang T, Guo Q, Li D, Bai G, Sun H, Wang W Cancer Manag Res. 2020; 12:11219-11230.

PMID: 33177873 PMC: 7649241. DOI: 10.2147/CMAR.S267345.


References
1.
Hoffman H, Porter K, Karnell L, Cooper J, Weber R, Langer C . Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006; 116(9 Pt 2 Suppl 111):1-13. DOI: 10.1097/01.mlg.0000236095.97947.26. View

2.
Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

3.
Zhou F, Nie L, Feng D, Guo S, Luo R . MicroRNA-379 acts as a tumor suppressor in non-small cell lung cancer by targeting the IGF‑1R-mediated AKT and ERK pathways. Oncol Rep. 2017; 38(3):1857-1866. DOI: 10.3892/or.2017.5835. View

4.
Kloosterman W, Plasterk R . The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006; 11(4):441-50. DOI: 10.1016/j.devcel.2006.09.009. View

5.
Gong Y, Wu W, Zou X, Liu F, Wei T, Zhu J . MiR-26a inhibits thyroid cancer cell proliferation by targeting ARPP19. Am J Cancer Res. 2018; 8(6):1030-1039. PMC: 6048401. View